Endomedix is a development stage MedTech firm that has developed a platform technology (PLEXimine™) based on novel polysaccharide chemistry.The first device using this technology will be PlexiClot™ Absorbable Hemostat for Brain & Spinal Surgeries, an underserved $1.7B market. Endomedix has been awarded 7 NIH SBIR Grants and has obtained 9 issued patents. After Neurosurgery, PlexiClot will be launched into other surgical subspecialties, such as OB/GYN, Cardiology, Plastic Surgery, Orthopedic Surgery, and General Surgery and have an application for Tissue Sealants, Tissue Engineering Devices, Drug Delivery, and Wound Care.

Led Commercial and Clinical Development of Seravue®, a novel Early Detection “Liquid Biopsy” AI Blood Test for Liver Cancer, which was granted FDA Breakthrough Device Designation on June 8th, 2020. Raised financing from NIH/NCI Phase 1, Phase 2, and Phase 2B SBIR Grants for $6.5M. Published Key Validation Study with Harvard Medical School.

National Institutes of Health (NIH) Commercialization Accelerator Program (CAP) is a nationwide program funded by NIH and managed by Larta, Inc.,an internationally-recognized technology accelerator that has helped more than 10,000 companies transform ideas into commercialized, socially-beneficial innovations in science and technology that aim to feed, fuel and heal the world.

10 Week Medical School Program that taught Biochemistry, Gross Anatomy, Histology, Microbiology, and Physiology. Only 70 students chosen out of 300.

Sparta Science is a Data Driven Athlete Development Software Technology Company.

Mentored by Dr. Joseph Ibrahim, Alumni Distinguished Professor of Biostatistics, in Bayesian Cancer Clinical Trials.